Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $170 Price Target
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.
